Medpace (NASDAQ:MEDP) PT Raised to $464.00 at Guggenheim

Medpace (NASDAQ:MEDP) had its price objective increased by research analysts at Guggenheim from $453.00 to $464.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim’s target price would indicate a potential upside of 19.04% from the company’s previous close.

Other research analysts have also recently issued reports about the company. StockNews.com raised Medpace from a “hold” rating to a “buy” rating in a report on Tuesday. Deutsche Bank Aktiengesellschaft started coverage on Medpace in a report on Monday, March 18th. They issued a “hold” rating and a $395.00 price target on the stock. Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and boosted their price target for the stock from $340.00 to $450.00 in a report on Tuesday. UBS Group raised Medpace from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $282.00 to $452.00 in a report on Thursday, February 15th. Finally, Robert W. Baird boosted their price target on Medpace from $446.00 to $454.00 and gave the stock an “outperform” rating in a report on Wednesday. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $443.00.

Medpace Trading Down 2.0 %

Shares of NASDAQ:MEDP opened at $389.77 on Wednesday. The stock has a 50 day moving average of $397.75 and a 200 day moving average of $324.12. The company has a market cap of $12.08 billion, a PE ratio of 39.73, a price-to-earnings-growth ratio of 2.04 and a beta of 1.38. Medpace has a 12-month low of $189.30 and a 12-month high of $421.00.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, April 22nd. The company reported $3.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.45 by $0.75. The company had revenue of $511.00 million during the quarter, compared to the consensus estimate of $512.39 million. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The firm’s revenue was up 17.7% on a year-over-year basis. During the same period in the previous year, the company posted $2.27 EPS. Equities research analysts predict that Medpace will post 11.13 earnings per share for the current fiscal year.

Insider Transactions at Medpace

In other news, VP Susan E. Burwig sold 102 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $403.00, for a total transaction of $41,106.00. Following the sale, the vice president now directly owns 15,181 shares of the company’s stock, valued at approximately $6,117,943. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, VP Susan E. Burwig sold 102 shares of the stock in a transaction on Friday, March 15th. The stock was sold at an average price of $403.00, for a total transaction of $41,106.00. Following the sale, the vice president now owns 15,181 shares in the company, valued at approximately $6,117,943. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ashley M. Keating sold 250 shares of the stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $409.87, for a total value of $102,467.50. Following the sale, the director now owns 250 shares in the company, valued at approximately $102,467.50. The disclosure for this sale can be found here. Insiders have sold 189,340 shares of company stock valued at $76,651,647 in the last ninety days. Corporate insiders own 20.30% of the company’s stock.

Institutional Trading of Medpace

Several hedge funds and other institutional investors have recently bought and sold shares of MEDP. RiverPark Advisors LLC purchased a new stake in Medpace during the 4th quarter valued at $26,000. Contravisory Investment Management Inc. bought a new position in Medpace in the 4th quarter valued at $26,000. Rise Advisors LLC bought a new position in Medpace in the 1st quarter valued at $27,000. Mather Group LLC. bought a new position in Medpace in the 1st quarter valued at $28,000. Finally, FinTrust Capital Advisors LLC bought a new position in Medpace in the 3rd quarter valued at $30,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.